Laurent Peyrin-Biroulet to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Randomized Controlled Trials as Topic.
Connection Strength
0.468
-
Time to include patients with ulcerative proctitis in clinical trials. Lancet Gastroenterol Hepatol. 2019 12; 4(12):900-902.
Score: 0.207
-
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Dig Liver Dis. 2019 03; 51(3):327-334.
Score: 0.048
-
Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22.
Score: 0.046
-
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 05; 16(5):637-647.e13.
Score: 0.044
-
E-health in inflammatory bowel diseases: More challenges than opportunities? Dig Liver Dis. 2017 Dec; 49(12):1320-1326.
Score: 0.044
-
Surgical rates in the era of biological therapy: up, down or unchanged? Curr Opin Gastroenterol. 2017 Jul; 33(4):246-253.
Score: 0.044
-
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol. 2019 10; 85(10):2244-2254.
Score: 0.013
-
Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):597-606.
Score: 0.011
-
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017 May; 45(10):1291-1302.
Score: 0.011